Mucin 1 tumor-associated glycoform CanAg (CanAg) (CanAg)

Mucin 1 tumor-associated glycoform CanAg, also known as the CA242 antigen, is a specific carbohydrate-rich glycoform of the Mucin 1 (MUC1) protein that is aberrantly expressed in various epithelial malignancies [1, 3, 5]. MUC1 is a large, type I transmembrane glycoprotein that normally functions as a protective and lubricating barrier on the apical surface of epithelial cells [5, 8]. In cancer cells, MUC1 is overexpressed and undergoes truncated or altered glycosylation, leading to the exposure of the CanAg epitope, which is highly prevalent in pancreatic, colorectal, gastric, and non-small cell lung cancers [1, 5, 16]. This tumor-associated glycoform contributes to disease progression by modulating intracellular signaling pathways, such as JNK and STAT3, and facilitating immune evasion and metastasis [9, 21, 22]. Because CanAg expression is minimal in normal tissues, it has been extensively explored as a target for antibody-drug conjugates (ADCs) [1, 5, 20]. Drugs such as cantuzumab mertansine and cantuzumab ravtansine utilize the huC242 antibody to deliver potent cytotoxic payloads directly to CanAg-positive cells, where they are internalized and released to induce cell death [5, 13, 16]. Despite promising preclinical results, therapeutic challenges include managing off-target toxicities and ensuring efficient delivery to bulky tumors [1, 5, 20].

Other names

Cancer Antigen 242CA242MUC1-CanAgSialylated carbohydrate tumor-associated antigenhuC242 target

Antibody-drug conjugates (ADCs) targeting CanAg bind to the extracellular epitope, undergo receptor-mediated endocytosis, and release cytotoxic payloads (e.g., tubulin inhibitors like DM1/DM4 or DNA alkylators like PBD) intracellularly to induce cell cycle arrest and apoptosis [5, 13, 20].